Carotid artery stenting with routine cerebral protection in high-risk patients.

Am J Surg

Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and the Methodist Hospital, HVAMC (112), 2002 Holcombe Blvd., Houston, TX 70030, USA.

Published: December 2004

Background: Carotid artery stenting has emerged as an alternative treatment modality in carotid occlusive disease. This study examined our experience of carotid stenting with routine cerebral embolization protection in high-risk patients.

Methods: Clinical variables and treatment outcome of high-risk patients who underwent carotid stenting with neuroprotection were analyzed during a 26-month period.

Results: Sixty-eight high-risk patients with 72 carotid artery stenoses were treated. Procedural success was achieved in 70 cases (97%), and symptomatic lesions existed in 17 (24%) patients. Monorail Wallstents stents were used in all cases. Neuroprotective devices used were PercuSurge (28%) and Filterwire (72%). There was no periprocedural mortality or neuroprotective device-related complications. The 30-day stroke and death rate was 2.7%, and the overall complication rate was 6.9%. All stented vessels remained patent during the follow-up period (mean 15.3 +/- 4.2, range 1 to 23 months). Two asymptomatic in-stent restenosis (3%) occurred at 6 and 8 months, which were both successfully treated with balloon angioplasty.

Conclusions: Our study showed that percutaneous carotid stenting with routine use of a cerebral protection device is a feasible and effective treatment in high-risk patients with carotid occlusive disease.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjsurg.2004.08.035DOI Listing

Publication Analysis

Top Keywords

high-risk patients
16
carotid artery
12
stenting routine
12
routine cerebral
12
carotid stenting
12
carotid
8
artery stenting
8
cerebral protection
8
protection high-risk
8
carotid occlusive
8

Similar Publications

Introduction And Aims: Dental practices pose a high risk of microbial contamination due to frequent exposure to bodily fluids like saliva and blood. Bioengineering innovations have emerged as vital tools to enhance infection control in dental settings. This review aims to assess the global applications and effectiveness of these innovations, particularly focusing on antimicrobial biomaterials, sterilization techniques, and personal protective equipment (PPE).

View Article and Find Full Text PDF

Background/aim: Gastrointestinal stromal tumors (GISTs) are rare cancers originating from Cajal's stromal cells in the gastrointestinal tract. The most common driver mutation in these cancers is the KIT mutation. This report presents a case of response to low-dose imatinib in a patient with GIST harboring KIT exon 11 W557_K558 deletion.

View Article and Find Full Text PDF

Background/aim: This study evaluated the diagnostic accuracy (DA) for colorectal adenomas (CRA), screened by fecal immunochemical test (FIT), using five artificial intelligence (AI) models: logistic regression (LR), support vector machine (SVM), neural network (NN), random forest (RF), and gradient boosting machine (GBM). These models were tested together with clinical features categorized as low-risk (lowR) and high-risk (highR).

Patients And Methods: The colorectal neoplasia (CRN) screening cohort of 5,090 patients included 222 CRA patients and 264 non-CRA patients.

View Article and Find Full Text PDF

Background/aim: Predictors of recurrence following resection of hepatocellular carcinoma (HCC) are not fully established. This study investigated potential risk factors and prognostic scores for this situation.

Patients And Methods: In 297 patients undergoing resection of HCC between 2000 and 2021, risk scores and potential additional risk factors for intrahepatic and extrahepatic recurrence were assessed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!